目的 分析天津市滨海新区汉沽中医医院门诊降糖药的使用情况及变化趋势,为临床合理用药提供参考。方法 采用回顾性分析方法,对2018-2021年天津市滨海新区汉沽中医医院门诊降糖药的销售金额、用药频度(DDDs)、日均费用(DDC)和排序比(B/A)等进行统计分析。结果 2018-2021年,门诊降糖药的销售金额和DDDs均呈逐年上升趋势。其中胰岛素类降糖药的销售金额连续4年稳居第1位。口服类降糖药中,α-糖苷酶抑制剂销售金额2018、2019年居首位,2020、2021年二肽基肽酶4(DPP-4)抑制剂跃升至第1位。具体口服药物中二甲双胍的销售金额和DDDs排序2018-2020年居首位,2021年利格列汀销售金额迅速上升至第1位,达格列净DDDs升至首位。除阿卡波糖、格列美脲、达格列净、恩格列净、二甲双胍、维格列汀、瑞格列奈外,其余口服降糖药各品种的DDC值均无明显浮动。注射类降糖药中,预混胰岛素类似物的DDDs排名连续4年始终位居第1位,其销售金额2018-2020年也居首位,2021年降至第2位,长效胰岛素类似物2018-2020年销售金额居第2位,2021年升至第1位,且销售金额逐年上升。除双胰岛素类似物、度拉糖肽、利拉鲁肽外,其余注射类降糖药的DDC值均基本稳定。注射类和口服类降糖药的B/A值均接近或等于1.00,说明同步性良好。结论 天津市滨海新区汉沽中医医院门诊降糖药使用基本合理,新型口服降糖药DPP-4抑制剂、SGLT2抑制剂使用量逐渐超过双胍类、α-糖苷酶抑制剂等传统口服降糖药。

Objective To analyze the use and change trend of hypoglycemic drugs in the outpatient department of Hangu Traditional Chinese Medicine Hospital in Tianjin Binhai New Area, so as to provide reference for clinical rational drug use. Methods The sales amount, DDDs, DDC and B /A of outpatient hypoglycemic drugs in Hangu Traditional Chinese Medicine Hospital in Tianjin Binhai New Area from 2018 to 2021 were statistically analyzed by retrospective analysis. Results From 2018 to 2021, the sales amount and DDDs of outpatient hypoglycemic drugs showed an upward trend year by year. Among them, the sales amount of insulin hypoglycemic drugs ranked first for four consecutive years. In oral hypoglycemic drugs, The sales amount of α-glycosidase inhibitors ranked first in 2018 and 2019, and DPP-4 inhibitors jumped to the first place in 2020 and 2021. Among the specific oral drugs, the sales amount and DDDs of metformin ranked first from 2018 to 2020, the sales amount of liggliptin rose rapidly to the first place in 2021, and the net DDDs of daggliptin rose to the first place. Except for acarbose, glimepiride, dalglitazin, engglitazin, metformin, vigliptin, and repaglinide, the DDC values of other oral hypoglycemic drugs did not fluctuate significantly. Among the injectable hypoglycemic drugs, the DDDs of premixed insulin analogues has always ranked first for four consecutive years, and its sales amount also ranked first from 2018 to 2020 and dropped to the second in 2021. The sales amount of long-acting insulin analogues ranked second from 2018 to 2020 and rose to the first in 2021, and the sales amount has increased year by year. The DDC values of other injectable hypoglycemic drugs were basically stable except for double insulin analogues, dulaglutide and liraglutide. The B/A values of injectable and oral hypoglycemic drugs are close to or equal to 1.00, indicating good synchronization. Conclusion The use of outpatient hypoglycemic drugs in Hangu Traditional Chinese Medicine Hospital in Tianjin Binhai New Area is basically reasonable. The use of new oral hypoglycemic drugs DPP-4 inhibitor and SGLT2 inhibitor gradually exceeds that of biguanidesα-glycosidase traditional oral hypoglycemic drugs such as glycosidase inhibitors.

R977